¹Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet. 2019;394(10204):1159–1168. doi: 10.1016/S0140-6736(19)31709-X. https://pubmed.ncbi.nlm.nih.gov/31474332/
Key takeaways
- Combined HRT (oestrogen plus progestogen) slightly increases breast cancer risk, roughly 5 extra cases per 1,000 women taking it for 5 years.
- Oestrogen-only HRT does not appear to increase risk, and some long-term studies suggest it may even be protective.
- The type of progestogen matters: micronised progesterone appears to carry lower risk than older synthetic progestogens.
If you are considering HRT, the question of breast cancer risk has probably crossed your mind. It is one of the most common concerns women raise, and it is completely understandable. Media coverage over the years has sent mixed messages, and the relationship between hormones and breast cancer is genuinely complex.
Here is what matters: the risk is real, but it is also nuanced. Not all HRT is the same. Not all women face the same level of risk. And for many women experiencing significant menopause symptoms, the evidence shows that the benefits of HRT outweigh the small increase in breast cancer risk.
This guide breaks down what the research actually shows, how different types of HRT affect risk, how your individual factors come into play, and how to think through the decision with proper specialist support. No scaremongering, no false reassurance. Just the evidence, explained clearly.
Does HRT increase breast cancer risk?
Yes, but the full answer is more nuanced than a simple yes or no.
Combined HRT (oestrogen plus a progestogen) does slightly increase breast cancer risk. The most comprehensive data comes from a 2019 meta-analysis published in The Lancet, which analysed data from 108,647 postmenopausal women with breast cancer. It found that all types of menopausal hormone therapy except vaginal oestrogens were associated with an increased risk, with combined preparations carrying higher risk than oestrogen-only HRT.
Oestrogen-only HRT tells a different story. The 20-year follow-up from the Women's Health Initiative, one of the largest randomised controlled trials of HRT, found that women taking oestrogen alone had lower breast cancer incidence (22% reduction) and lower breast cancer mortality (40% reduction) compared to placebo. Oestrogen-only HRT does not increase risk and may even be protective.
Vaginal oestrogen (topical treatments for vaginal dryness and urinary symptoms) does not increase breast cancer risk. This is consistently shown across multiple studies and reflected in NICE guidelines.
The key point: HRT is not a single treatment. The type you take, the dose, the duration, and your individual risk factors all shape your overall risk profile.
How different types of HRT affect breast cancer risk
Not all HRT formulations carry the same level of risk. Understanding the differences can help you and your specialist choose the approach that balances symptom relief with your personal risk tolerance.
Combined HRT (oestrogen plus progestogen)
Combined HRT is prescribed for women who still have a uterus, with progestogen added to protect the uterine lining from overgrowth caused by oestrogen alone.
According to the 2019 Lancet meta-analysis, combined HRT carries a slightly higher breast cancer risk than oestrogen-only HRT, and this risk increases with duration of use. For context, five years of combined HRT starting at around age 50 is associated with approximately 5 extra breast cancer cases per 1,000 women, a modest absolute increase for most women.
Oestrogen-only HRT
Oestrogen-only HRT is an option for women who have had a hysterectomy, as there is no uterine lining to protect.
Long-term research has found that women taking oestrogen alone had lower rates of breast cancer compared to those taking no hormones at all. NICE guidance confirms that oestrogen-only HRT carries little or no increased breast cancer risk. If you have had a hysterectomy and are considering HRT, this is reassuring.
Vaginal oestrogen
Vaginal oestrogen (creams, pessaries, or rings used for vaginal dryness and urinary symptoms) is absorbed locally rather than systemically. Multiple studies and guidelines confirm it does not increase breast cancer risk. If your main concern is vaginal or urinary symptoms and you are worried about systemic HRT, vaginal oestrogen is a safe and highly effective option.
Body-identical vs synthetic progestogens
The type of progestogen matters. Body-identical progesterone (micronised progesterone) and dydrogesterone appear to carry lower breast cancer risk than older synthetic progestogens, a distinction the British Menopause Society explicitly recognises. It is worth asking your specialist which type of progestogen is most appropriate for you.
Understanding the numbers: absolute vs relative risk
When you read "HRT increases breast cancer risk," the natural reaction is alarm. But the numbers are worth understanding properly.
Using NHS baseline data: without HRT, about 23 in every 1,000 women aged 50 to 59 will develop breast cancer over 5 years. With combined HRT for 5 years, that rises to about 28 in every 1,000, an increase of 5 extra cases. Put another way: 995 out of 1,000 women taking combined HRT for 5 years will not develop breast cancer.
Headlines often report risk in relative terms, for example "30% increased risk." This sounds alarming but describes the proportional change, not the actual likelihood. A 30% relative increase on a low baseline is still a small absolute risk. A 30% relative increase on a 2% baseline brings it to 2.6%, still a low number. Understanding this distinction helps you put the figures in perspective and assess whether the risk is meaningful for you in the context of your symptoms and quality of life.
For women with a family history, recent modelling from the Institute of Cancer Research found that 5 years of combined HRT increased absolute lifetime risk from 9.8% to 11% for women with average risk, and from 17% to 19.8% for women with a strong family history. The increase is real but modest even for higher-risk groups.
How long you take HRT matters
The duration of HRT use directly affects breast cancer risk. This is one of the most consistent findings across all the major studies.
Under 5 years: the breast cancer risk increase is very small. For many women, this is the window where symptom relief is most needed: the early years of menopause when hot flushes, sleep disruption, and mood changes are most severe.
5 to 10 years: risk increases with duration. The Lancet meta-analysis found that for every year of combined HRT use, the risk continues to increase, though it remains relatively modest for most women.
Beyond 10 years: risk accumulates further. Research from the Million Women Study found that past users with 5 or more years of prior HRT use had a significantly elevated breast cancer mortality risk over the following 20 years.
What happens when you stop?
The good news: breast cancer risk associated with HRT declines after stopping. A 2020 study using UK primary care data covering 98,611 breast cancer cases found that risks declined more quickly after stopping than some earlier studies suggested. Within 2 to 3 years of stopping, the excess risk drops substantially. By 5 years, the risk has largely returned to baseline for most women.
The "5-year guideline"
You may have heard that HRT should only be taken for a maximum of 5 years. This is not a hard rule. It is a general guideline based on the risk-benefit balance. NICE guidance suggests that for most women, the benefits of taking HRT for up to 5 years outweigh the risks. Beyond that, the decision should be reviewed individually with a specialist, weighing ongoing symptom relief against cumulative risk. The British Menopause Society recommends that treatment be reviewed regularly (typically annually) and continued for as long as the benefits outweigh the risks for that individual woman.
HRT risk compared to other lifestyle factors
Context matters when assessing HRT risk. How does the 5 extra cases per 1,000 women from 5 years of combined HRT compare to other modifiable risk factors?
Alcohol: regular alcohol consumption carries a well-established breast cancer risk. Drinking 2 to 3 units per day is associated with approximately 7 extra cases per 1,000 women, higher than the HRT increase.
Obesity: being overweight or obese after menopause is associated with approximately 12 extra cases per 1,000 women compared to a healthy BMI, again higher than the HRT increase.
Physical inactivity and having children later in life or not at all are also associated with increased breast cancer risk.
This does not mean HRT risk does not matter. It means the risk needs to be considered alongside all modifiable factors. A comprehensive approach to breast cancer risk reduction includes maintaining a healthy weight, limiting alcohol, staying active, and making informed decisions about HRT with specialist guidance.
Should you take HRT if you have a family history of breast cancer?
Having a family history of breast cancer does not automatically mean HRT is off the table. It does mean the decision needs more careful thought and specialist input.
The ICR's 2024 risk modelling study specifically addressed this. For women with a strong family history (defined as two or more close relatives affected), 5 years of combined HRT increased their absolute lifetime breast cancer risk from 17% to 19.8%, an increase of 2.8 percentage points. This is larger than the 1.2 percentage point increase for women with average risk, but still a relatively modest absolute increase. Importantly, 80% of women with a strong family history who take HRT for 5 years will not develop breast cancer by age 80.
NICE guidance recommends specialist referral if you have a known genetic mutation (BRCA1, BRCA2, or other high-risk genes), a very strong family history suggesting hereditary breast cancer, or a previous breast cancer diagnosis. In these cases, HRT is not necessarily contraindicated, but the assessment needs to be done by a specialist who can weigh your specific genetic risk, symptom severity, and alternative treatment options.
Voy's 45-minute consultations with British Menopause Society-trained menopause specialists give you the time to discuss your family history in detail, assess your individual risk factors, and explore treatment options. Take our short quiz to find out whether specialist menopause care could help you.
What if you have had breast cancer?
If you have had breast cancer, the question of HRT is more complex and requires specialist guidance from both a menopause expert and your oncology team.
NICE guidance states that HRT is generally not recommended for women who have had breast cancer, particularly hormone-receptor-positive breast cancer. However, the guidance also notes that for women with severe symptoms significantly affecting quality of life, the decision should be made on a case-by-case basis after thorough discussion of the risks. A 2026 multidisciplinary consensus statement reinforces this, concluding that decisions should be based on the individual's symptom burden, their risk of relapse, and their own preferences and treatment goals.
“Even if systemic HRT is not suitable, other options exist. Vaginal oestrogen is safe for local genitourinary symptoms and does not increase breast cancer risk and is often the first-line option for vaginal dryness, discomfort during sex, and urinary symptoms. Non-hormonal treatments including SSRIs, SNRIs, gabapentin, and CBT can also manage symptoms without hormones. Women with a history of breast cancer deserve high-quality menopause care, even when systemic HRT is contraindicated.”
The benefits of HRT
Understanding breast cancer risk is crucial, but it is only half the equation. The other half is understanding what HRT can do for quality of life.
HRT is the most effective treatment for menopause symptoms. Hot flushes and night sweats are reduced by 70 to 90% in most women. 71% of Voy members reported improved sleep after treatment, 83% saw improvement in mood and emotional symptoms, and 73% experienced clearer thinking. 93% reported improvement in overall quality of life after starting treatment.
Beyond symptom relief, HRT offers long-term protective benefits. Oestrogen protects against osteoporosis and reduces fracture risk. When started around the time of menopause, HRT appears to have cardiovascular benefits or neutral effects. When started more than 10 years after menopause, it may carry different cardiovascular risks, which is why timing is part of any individualised assessment.
This "timing hypothesis" is now well established: starting HRT within 10 years of menopause (or under age 60) carries a different risk-benefit profile than starting it much later. If you are currently experiencing menopause symptoms and considering HRT, you are in the window where the evidence is most favourable.
When to seek help at Voy
The decision about HRT is not one-size-fits-all. It depends on your symptoms, your risk factors, your medical history, and what matters most to you in terms of quality of life.
Voy's menopause care starts with a 45-minute consultation with a British Menopause Society-trained menopause specialist. Your specialist will take a comprehensive medical history including family history of breast cancer, assess your symptoms in depth, discuss your individual risk, explain your treatment options (including different types of HRT), build a personalised treatment plan, and set up ongoing monitoring at 3, 6, and 12 months.
88% of Voy members felt more hormonally balanced at 3 months, compared to 62% receiving standard care. Take our short quiz to find out whether specialist menopause care is right for you.
